Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.448
+0.034 (8.12%)
At close: Mar 9, 2026, 4:00 PM EDT
0.423
-0.025 (-5.47%)
After-hours: Mar 9, 2026, 5:48 PM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$12,100
Profits / Employee
-$6,050,624
Market Cap
37.18M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Atara Biotherapeutics | 38 |
| Lisata Therapeutics | 26 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| INmune Bio | 22 |
| ABVC BioPharma | 19 |
OTLK News
- 4 days ago - Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 18 days ago - Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - GlobeNewsWire
- 20 days ago - Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 26 days ago - Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - GlobeNewsWire
- 2 months ago - US FDA declines to approve Outlook Therapeutics' eye disease drug - Reuters
- 2 months ago - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again - Seeking Alpha